Research by Haley A. Moss, MD, MBA, Gynecological Oncology Fellow, and colleagues, shows that multimodal screening (MMS) for ovarian cancer is potentially cost-effective in the U.S. The study has been published in JAMA Oncology. An article on the research appears in the December 8, 2017 edition of HealthDay.